|
WO2017049286A1
|
|
Polynucleotides containing a morpholino linker
|
|
WO2017049074A1
|
|
Polynucleotide formulations for use in the treatment of renal diseases
|
|
US2016289674A1
|
|
Modified polynucleotides for the production of membrane proteins
|
|
WO2016164762A1
|
|
Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
|
|
US2016158385A1
|
|
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
|
US2018000953A1
|
|
Lipid nanoparticle compositions
|
|
EP3247398A1
|
|
Lipid nanoparticle compositions
|
|
WO2016100812A1
|
|
Terminal modifications of polynucleotides
|
|
WO2016077123A1
|
|
Multiparametric nucleic acid optimization
|
|
EP3188749A1
|
|
Tolerogenic compositions and methods
|
|
HK1206612A1
|
|
Modified polynucleotides for the production of secreted proteins
|
|
HK1206749A1
|
|
Modified polynucleotides
|
|
WO2016011226A1
|
|
Chimeric polynucleotides
|
|
WO2016011222A2
|
|
Circular polynucleotides
|
|
EP3157573A2
|
|
Alternative nucleic acid molecules and uses thereof
|
|
WO2015196130A2
|
|
Alternative nucleic acid molecules and uses thereof
|
|
WO2015196118A1
|
|
Alternative nucleic acid molecules and uses thereof
|
|
US2015246139A1
|
|
Modified polynucleotides for the production of nuclear proteins
|
|
EP3092250A1
|
|
Polynucleotides for the in vivo production of antibodies
|
|
US2017002060A1
|
|
Polynucleotides for the in vivo production of antibodies
|
